MARKET

RAPT

RAPT

Rapt Therapeutics, Inc.
NASDAQ
1.310
+0.110
+9.17%
After Hours: 1.310 0 0.00% 19:57 03/21 EDT
OPEN
1.180
PREV CLOSE
1.200
HIGH
1.345
LOW
1.160
VOLUME
4.67M
TURNOVER
--
52 WEEK HIGH
9.65
52 WEEK LOW
0.7893
MARKET CAP
172.93M
P/E (TTM)
-0.4112
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RAPT last week (0310-0314)?
Weekly Report · 5d ago
Rapt Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Dow Jones · 03/10 11:55
Weekly Report: what happened at RAPT last week (0303-0307)?
Weekly Report · 03/10 11:39
RAPT Therapeutics: Strategic Licensing and Strong Cash Position Support Buy Rating Despite Financial Loss
TipRanks · 03/10 10:26
RAPT Therapeutics to Participate in Upcoming Investor Conferences
Barchart · 03/07 15:30
Promising Developments and Strategic Trials Boost RAPT Therapeutics’ Buy Rating
TipRanks · 03/07 11:56
RAPT Therapeutics Focuses on RPT904 Development in 2025
TipRanks · 03/07 04:19
RAPT THERAPEUTICS, INC. FORM 10-K
Press release · 03/06 20:34
More
About RAPT
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its drug discovery and development engine, it develops selective small molecules designed to modulate the critical immune responses underlying these diseases. Its lead inflammation drug candidate, zelnecirnon (RPT193), and its lead oncology drug candidate, tivumecirnon (FLX475), each target C-C motif chemokine receptor 4 (CCR4), a drug target that potentially has broad applicability in inflammatory diseases and oncology. Its inflammation drug candidate, zelnecirnon, is designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its oncology drug candidate, tivumecirnon, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors.

Webull offers Rapt Therapeutics Inc stock information, including NASDAQ: RAPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RAPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RAPT stock methods without spending real money on the virtual paper trading platform.